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207in 38,602 patients (nonshunt group). An intracardiac shunt was
identiﬁed in 418 patients in the perﬂutren group (40 detected at
rest only, 128 detected following Valsalva maneuver only, 84
detected with both; 166 unknown). Patients with left-to-right
shunts only (n ¼ 63; detected by color Doppler) were excluded
from analysis. No primary adverse events occurred in the shunt
group; 1 occurred in the nonshunt group (p ¼ 0.99) (Table 1). One
secondary adverse event occurred in the shunt group, and 34 in the
nonshunt group (p ¼ 0.31). All events occurred in studies using
Deﬁnity (vs. Optison; p ¼ 0.03). Right heart contrast studies were
performed in 3,661 patients (1,432 with perﬂutren, 2,229 without
perﬂutren); intracardiac shunts were diagnosed in 839 patients
(23%).
The International Contrast Ultrasound Society recently raised
concerns about the current contraindication of perﬂutren use in
patients with known/suspected intracardiac shunts, recommending
that this contraindication be removed to improve patient care and
reduce unnecessary downstream testing (1). Agitated saline, a ﬁrst-
generation echocardiographic contrast agent (hand-agitated, with
tremendous heterogeneity in bubble size) has been widely used
during transthoracic and transesophageal echocardiograms to detect
intracardiac shunts, without regulatory oversight (1). However, the
greater diffusibility of air in the circulation, and lack of CARPA
reactions to agitated saline, probably do not allow for a direct
comparison with perﬂutren. The current observational study is the
ﬁrst to assess the use of perﬂutren in patients with intracardiac
shunts, and it demonstrates that the overall incidence of adverse
events was low in patients receiving perﬂutren. Importantly, per-
ﬂutren use in patients with these shunts (without cyanotic
congenital heart disease) was not associated with signiﬁcant adverse
neurological and/or systemic embolic events compared with use in
patients without diagnosed intracardiac shunts. Similarly, perﬂutrenTable 1. Primary and Secondary Adverse Events With Perﬂutren-Based
Echocardiographic Contrast Agent Use in Patients With and Without
Right-to-Left, Bidirectional, or Transient Right-to-Left Intracardiac Shunts
Intracardiac Shunt
Total p ValueYes No
Perﬂutren-based ECA use 418 38,602 39,020
Primary adverse events 0 1 1 0.99
Transient ischemic attack 0 1 (0.0026)
Secondary adverse events 1 34 35 0.31
Angioedema 0 1 (0.0026)
Back pain 1 (0.24) 24 (0.0622)
Bronchospasm 0 1 (0.0026)
Hypotension 0 2 (0.0052)
Hypoxemia 0 1 (0.0026)
Urticaria 0 4 (0.0104)
Vasovagal reaction 0 1 (0.0026)
Other events 0 1 1
Seizure 0 1 (0.0026)
Values are n or n (%).
ECA ¼ echocardiographic contrast agent.use was not associated with any signiﬁcant difference in secondary
adverse events (CARPA reaction) in patients with intracardiac
shunts. Of note, all CARPA reactions in our cohort occurred with
use of Deﬁnity and were consistent with previously published data
from our laboratory (2).
Study limitations include potential underestimation of adverse
event incidence due to incomplete registry ascertainment, occurrence
more than 30 min after perﬂutren administration, or occurrence in
sedated or unconscious patients. Also, relatively modest numbers of
intracardiac shunts were noted in the perﬂutren group, which was
attributable to potential selection bias and possibly the impact of the
Food and Drug Administration’s 2001 contraindication of perﬂutren
use in patients with intracardiac shunts.
The current proscription of perﬂutren is logically untenable in
clinical practice, as it is based on a “don’t ask, don’t tell” paradigm
for shunt detection in patients who are potential candidates for
receiving perﬂutren. Our data indicate that the current proscription
of perﬂutren use in patients with intracardiac shunts should be
rescinded.
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LV Noncompaction
in Ebstein’s Anomaly in Infants and
Outcomes
Left ventricular noncompaction (LVNC) is a distinct primary
myocardial disease characterized by abnormally prominent tra-
beculations in the ventricular myocardium, and is reported to
coexist with congenital heart diseases like Ebstein’s anomaly
(EA) and others (1). The clinical course of LVNC with EA is
unknown in the pediatric literature. We report a pediatric cohort
of LVNC and EA, with emphasis on the natural course and the
outcome.
We conducted a retrospective search of our institutional data-
base from 2002 to 2007 for patients with EA and LVNC. This
cohort was divided into 2 groups: group 1, patients with EA and
LVNC; and group 2, patients with EA alone. We reviewed
patients’ medical records and collected information on the age at
diagnosis, clinical presentation, electrocardiographic features,
echocardiographic severity of the LVNC based on the extent of
Figure 1. Correlation of Pathologic Findings and 2D Echocardiography in Ebstein’s Anomaly and LVNC
(A) Autopsy specimen of a neonate with Ebstein’s anomaly, with right atrium opened to show the small right ventricle, plastered septal leaﬂet (arrowheads), and (B)
the dense trabeculations with recesses in the left ventricle (LV) (arrow). (C) Echocardiogram in the apical 4-chamber view, showing the trabeculations in the LV
(arrow). (D) Ebstein’s anomaly (arrows) with prominent trabeculations in the lateral wall of the LV (*), and (E) showing the displaced septal leaﬂet of the tricuspid
valve (**). 2D ¼ 2-dimensional; C ¼ compacted myocardium; LVNC ¼ left ventricular noncompaction; NC ¼ noncompacted myocardium with trabeculations.
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208distribution of abnormal myocardial trabeculations (the extent of
the distribution of abnormal left ventricular [LV] myocardial
trabeculations to the lateral wall, apex, and the ventricular septum
were labeled as segments 1, 2, and 3, respectively), LV end-
diastolic dimension indexed to the body surface area (with
z scores), ejection fraction (by Simpson biplane method) at initial
diagnosis and at latest follow-up, management (medical therapy,
catheter interventions, and surgeries), length of follow-up (in
months), and the outcome (alive or dead). All echocardiograms
were reviewed for LVNC, as deﬁned by the standard echocar-
diographic criteria, by 2 independent observers blinded to clinical
data.
Sixty-one patients were identiﬁed; 10 patients (16%) showed EA
and LVNC (group 1) (Fig. 1). The remaining 51 patients (84%)
showed EA alone (group 2). Nine of 10 patients (90%) in group 1
were diagnosed at birth with a suspicion of LVNC on the fetal
echocardiogram. In addition, 4 of 10 patients (40%) showed
cyanosis at birth, with right-to-left shunting across the patent fo-
ramen ovale. All patients in this group showed involvement of LV
segments 1 and 2, with an additional 3 patients showing involve-
ment of LV segment 3. There were no signiﬁcant differences in the
electrocardiographic ﬁndings: incidence of right bundle branch
block, ventricular pre-excitation, or supraventricular tachycardia
among these 2 groups.
The risk for an adverse clinical outcome was higher in group 1.
Five of 10 patients (50%) in this group developed progressive LV
dysfunction, of whom 3 (30%) died due to refractory congestiveheart failure. Of the patients surviving beyond the neonatal period,
the risk for progressive LV dysfunction was higher in group 1 (5 of
10 patients; 50%) compared with group 2 (4 of 51 patients; 8%)
(relative risk: 6.375; 95% conﬁdence interval: 2.06 to 19.66). The
risk of death in group 1 was 30% (3 of 10 patients) versus 13% (7 of
51 patients) in group 2 (relative risk: 2.185; 95% conﬁdence interval:
0.67 to 7.04).
We looked at the effect of LVNC on the outcome over short-
term follow-up. Coexistent LVNC led to early diagnosis, often
in utero as fetal hydrops or in the neonatal period as cyanosis,
and presented with refractory heart failure leading to death in
30% in the neonatal period. In addition, over 50% of those
surviving past the neonatal period developed progressive LV
dysfunction requiring either medical therapy or additional in-
terventions. In contrast, the mortality was relatively low (13%) in
group 2, with 44 surviving patients and 2 patients (5%) devel-
oping progressive LV dysfunction due to dilated cardiomyopathy
and requiring cardiac transplantation. Excluding deaths in the
neonatal period, the relative risk for adverse outcomedeither
development of LV dysfunction, congestive heart failure, or
deathdwas higher in group 1 versus group 2. Overall, patients
with EA with no evidence of LVNC surviving past the neonatal
period did well, with 95% remaining asymptomatic with normal
ventricular function.
In summary, we noted a trend toward early detection and adverse
outcome in group 1 patients. However, this study was limited by
small numbers (10 patients), and we did not look at the severity of
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209EA as a contributory factor. LVNC is known to show a variable
genotypic–phenotypic clinical expression, with mutations involving
several genes, and whether any of these mutations represents a
speciﬁc marker for EA or for a poor outcome is unknown. Our case
series extends support for in-depth studies for better understanding
of these 2 conditions (1).
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